Technology | Balloon Catheter | March 21, 2018

Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance of Sapphire II Pro 1mm Coronary Balloon

Device is the smallest 510(k)-cleared coronary balloon in the U.S. market

Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon

March 21, 2018 — Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the OrbusNeich 1mm Sapphire II Pro coronary balloon.

The Sapphire II Pro, the first and only 1mm coronary balloon available in the U.S., offers industry-leading entry and crossing profiles, according to the company, and is precision engineered for crossing and treating extremely tight and complex lesions.

In January, CSI announced it is the exclusive U.S. distributor of OrbusNeich balloon products. OrbusNeich is a globally recognized corporation with established balloon technologies in both percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA).

“As physicians, we have continued to advance techniques and expand access to interventional cardiology procedures. As a result, the patients we are treating today have become increasingly complex, with more challenging lesions and anatomy, and with more difficult clinical indications,” according to David E. Kandzari, M.D., director of interventional cardiology and chief scientific officer, Piedmont Heart Institute, Atlanta, and principal investigator for the Sapphire II PRO U.S. Clinical Study. “With its exceptionally low profile and deliverability, the Sapphire II Pro is an important new tool to enable us to better treat the patients we serve.”

At launch, CSI will offer both the 1-4mm Sapphire II Pro and the 2-4mm Sapphire NC Plus non-compliant coronary balloons on a limited basis. The company anticipates that OrbusNeich’s full balloon product portfolio will become available in the U.S. throughout 2018 and 2019.

For more information: www.orbusneich.com

Related Content

Feature | ACC | By Dave Fornell, Editor

Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 ...

Home June 08, 2021
Home
Feature | ACC | Dave Fornell, Editor

The latest cardiology practice-changing scientific breakthrough, late-breaking study presentations have been announced ...

Home May 18, 2021
Home
Feature | ACC

February 22, 2021 — The American College of Cardiology (ACC) moved its meeting from March to May 2021 in hopes that ...

Home February 22, 2021
Home
News | ACC | By Dave Fornell, Editor

UPDATE Feb 22, 2021 — ACC Abandons In-person Meeting and Goes Entirely Virtual for 2021 Due to COVID February 9, 2021 — ...

Home February 09, 2021
Home
Feature | ACC | Dave Fornell, Editor

Here is the list of American College of Cardiology (ACC) practice-changing late-breaking study presentations at the ACC ...

Home April 09, 2020
Home
Feature | ACC | Dave Fornell, Editor

March 9, 2020 — Less than week after the American College of Cardiology (ACC) said it would push ahead with holding its ...

Home March 09, 2020
Home
News | ACC

October 8, 2019 — Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of ...

Home October 08, 2019
Home
Feature | ACC | Greg Freiherr, Contributing Editor

The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the annual ...

Home March 27, 2019
Home
Feature | ACC

The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.19 ...

Home March 19, 2019
Home
Feature | ACC | Dave Fornell

There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American College ...

Home March 27, 2018
Home
Subscribe Now